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ABSTRACT
Introduction: Smoking is a major avoidable cause of
ill-health and premature death. Treatments that help
patients successfully quit smoking have an important
effect on health and life expectancy. Varenicline is a
medication that can help smokers successfully quit
smoking. However, there are concerns that it may
cause adverse effects, such as increase in the
occurrence of depression, self-harm and suicide and
cardiovascular disease. In this study we aim to
examine the effects of varenicline versus other
smoking cessation pharmacotherapies on smoking
cessation, health service use, all-cause and cause-
specific mortality and physical and mental health
conditions.
Methods: In this project we will investigate the effects
of varenicline compared to nicotine replacement
therapies on: (1) long-term smoking cessation and
whether these effects differ by area level deprivation;
and (2) the following clinically-important outcomes:
rate of general practice and hospital attendance; all-
cause mortality and death due to diseases of the
respiratory system and cardiovascular disease; and a
primary care diagnosis of respiratory illness,
myocardial infarction or depression and anxiety. The
study is based on a cohort of patients prescribed these
smoking cessation medications from the Clinical
Practice Research Datalink (CPRD). We will use three
methods to overcome confounding: multivariable
adjusted Cox regression, propensity score matched Cox
regression, and instrumental variable regression. The
total expected sample size for analysis will be at least
180 000. Follow-up will end with the earliest of either
an ‘event’ or censoring due to the end of registration
or death.
Ethics and dissemination: Ethics approval was not
required for this study. This project has been
approved by the CPRD’s Independent Scientific
Advisory Committee (ISAC). We will disseminate our
findings via publications in international peer-reviewed
journals and presentations at international
conferences.
INTRODUCTION
Smoking is the major cause of preventable
morbidity and mortality in the UK and inter-
nationally.1 2 Smoking is also the principal
cause of health inequalities and is respon-
sible for most of the difference in healthy
life-expectancy between the richest and
poorest in our society3 and those with and
without mental health problems.4 5
Smoking-related illnesses are estimated to
cost the NHS approximately £5billion per
year.6 Varenicline has been shown to be the
most clinically effective smoking cessation
medicine for short-term abstinence in
Strengths and limitations of this study
▪ We will use data from a large sample of patients
prescribed smoking cessation treatment in UK
general practices. This means we will have sub-
stantial power to detect even relatively small
effects, or effects on rare outcomes.
▪ We will use three statistical approaches to over-
come confounding. These approaches depend
on distinct assumptions. Triangulating across
different methods will help provide more robust
evidence about the effects of these medications.
▪ Our study will use observational data and so
results can suffer from unobserved confounding.
We will report in detail the confounding struc-
ture, and detail the methods we used to over-
come this limitation.
▪ The outcomes used in this study will be defined
using diagnoses and interactions that occur as
part of the patients’ routine care. Different
general practices may use a range of Read codes
to record diagnoses. We will mitigate this limita-
tion by using validated code lists, where avail-
able, to ensure the algorithms we use accurately
capture the diagnoses and events of interest.
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randomised controlled trials (RCTs).7 However, there is
relatively little evidence for its long-term effectiveness
and impact on clinical outcomes.
Concerns have been raised that varenicline may be
associated with a higher risk of adverse events, including
suicide and self-harm and cardiovascular events, than
other smoking cessation interventions.8–11 In 2009, the
US Food and Drug Administration (FDA) mandated
that varenicline carry a black box warning (the agency’s
strongest safety warning) highlighting the increased risk
of suicidal ideation and depression in patients pre-
scribed varenicline. This was based on spontaneous
reports to the FDA Adverse Events Reporting (FDA
AERS) database.12 These warnings are meant to indicate
causal effects of pharmaceuticals. However, there are an
increasing number of experimental and observational
studies that suggest there is little difference in risk of
adverse neuropsychiatric effects of varenicline compared
to nicotine replacement products.11 13 In October 2014,
the FDA decided that the black box warning on vareni-
cline should remain; it is expected that this guidance
will be updated after publication of the results of the
EAGLES randomised trial in late 2015.14 15
Much of the evidence about the potential adverse
effects of varenicline comes from observational studies,
which are prone to confounding. We will add to the evi-
dence base about the possible adverse and beneﬁcial
effects of prescribing different smoking cessation medi-
cations using three statistical approaches to overcome
confounding: multivariable adjusted regression, propen-
sity score regression and instrumental variable analysis.
Using these three approaches we aim to examine the
effects of varenicline versus other smoking cessation
pharmacotherapies on smoking cessation, health service
use, all-cause and cause-speciﬁc mortality and physical
and mental health conditions. Follow-up will end with
the earliest of either an ‘event’ or censoring due to the
end of registration or death. We will not investigate
bupropion because it is rarely prescribed and systematic
reviews have found that it is less effective than vareni-
cline for smoking cessation.7
Study aims
1. What is the effect of varenicline on smoking abstin-
ence? We will investigate the effects of varenicline on
smoking abstinence because existing evidence from
RCTs typically only followed participants for 1 year,
and are not informative about long-term outcomes.
2. What are the effects of varenicline on NHS service
use? We will investigate the effects of varenicline pre-
scriptions on all-cause primary and secondary care
utilisation because smoking increases morbidity and
imposes major costs on the healthcare services.16
3. What are the effects of varenicline on all-cause and
cause-speciﬁc mortality? We will investigate the inci-
dence illnesses in the Clinical Practice Research
Database (CPRD) using primary care diagnoses,
admission to secondary care using ICD-10 codes, and
Ofﬁce of National Statistics (ONS) mortality records
to maximise the number of events detected.
4. What are the effects of varenicline on common phys-
ical and mental health conditions? We will investigate
the effects of varenicline on rates of cardiovascular
outcomes and respiratory illnesses, as previous
research has suggested that patients prescribed vare-
nicline may have different rates of these outcomes.9 10
Second, we will investigate the effects of varenicline
on rates of depression and anxiety because there has
been some reports that varenicline may reduce the
risk of these outcomes.13
5. We will also examine differences in smoking cessation
medication effectiveness by socioeconomic position.
A recent systematic review reported that stop-smoking
services may be helping to reduce inequalities in
smoking prevalence by preferentially targeting
smokers of lower socioeconomic position (SEP). Data
from primary care records The Health Improvement
Network (THIN) show that between 2008 and 2010,
smokers in more deprived groups were more likely to
receive smoking cessation interventions.17
METHODS AND ANALYSIS
We will conduct a prospective cohort study of all
patients prescribed varenicline or nicotine replacement
products in the CPRD. Variables will be deﬁned using
‘Read codes’ which are clinical encoding of patient
phenomena, for example a patient’s: occupation, demo-
graphic information, social circumstances, clinical symp-
toms and observations, laboratory tests and results, and
diagnoses.
Inclusion and exclusion criteria
We will include patients who were older than 18 and
were prescribed medicines in British National Formulary
(BNF) category 4.10.2 (Nicotine Dependence) from 1
September 2006, when varenicline was introduced to the
UK, to the present. We will use patients prescribed other
smoking cessation products (nicotine patches, gum,
lozenges, and inhalers) as controls for patients pre-
scribed varenicline. We will include patients whose
records were classiﬁed as ‘acceptable’ by the CPRD from
all ‘up to standard’ general practices (GPs) at least
18 months prior to date of entry of each cohort (1st
March 2005). Up to standard GPs are practices that have
submitted data that meets the CPRD quality control
thresholds. Patient data are deﬁned as ‘acceptable’ by
the CPRD if they meet minimum quality control stan-
dards, for example their registration period with their
GP is valid.
We will exclude patients who registered at a GP less
than 365 days before the ﬁrst recorded prescription, to
allow for high-quality assessment of baseline data and
possible confounders. Patients prescribed bupropion in
the year before their index prescription of varenicline or
nicotine replacement therapy will be excluded from the
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analysis. In the primary analysis we will exclude patients
initially prescribed nicotine replacement therapies and
varenicline together, although in our previous analysis
this only occurred for 0.25% of all prescriptions.13
Power calculations
The following power calculations are based on effect
sizes and CIs observed in our previously published
results, which used data from 110 000 individuals pre-
scribed either varenicline or nicotine replacement
therapy.13 Based on the rate of 18 000 new prescriptions
per year observed in the CPRD from 2006 to 2011,13 we
estimate that with a further 4 years of follow-up the
number of patients prescribed either varenicline or
nicotine replacement therapy will have increased by
72 000. Therefore the total expected sample size for ana-
lysis will be around 180 000.
In our previous analysis using CPRD data the
age-adjusted and sex-adjusted HR for self-harm/suicide
for varenicline versus nicotine replacement therapy at
9 months was 0.73 (95% CI 0.54 to 0.99); after adjusting
for possible confounders this became 0.90 (95% CI: 0.66
to 1.22).13 A 70% increase in sample size would lead to
a reduction of the SE by a factor of 1.3, reducing the
breadth of the above CI in the adjusted analysis from
0.56 to 0.43.
Rare outcomes, such as self-harm and suicide were
used in previous analyses; in this project we will have
greater power to explore more common outcome mea-
sures. For example, in the previous analysis the
9-month age-adjusted and sex-adjusted HR for all-cause
mortality 9 months after ﬁrst prescription for vareni-
cline versus nicotine replacement therapy was 0.43
(95% CI 0.35 to 0.53); after controlling for possible
confounders this became 0.49 (95% CI 0.40 to 0.61).
A 70% increase in sample size would lead to a reduc-
tion of the SE by a factor of 1.3, reducing the breadth
of the above CI in the adjusted analysis from 0.21 to
0.16.
For the effects of varenicline versus nicotine replace-
ment therapy on all-cause mortality, instrumental
variable analysis found a risk difference of 0.7 (95%
CI −3.3 to 4.7) per 1000 patients treated after 9 months.
We estimate that a 70% increase in sample size would
narrow the CIs from 8.0 to 6.2.
Using data from our previous project, within 2 years of
ﬁrst prescription, we found 2517 admissions for respira-
tory disease among 1374 patients; 3144 admissions for
cardiovascular disease among 1022 patients; and 3277
admissions for depression or anxiety among 213
patients. This is more events than we found for suicide
and self-harm in our previous study; therefore we believe
that there will be enough events for this analysis.
To investigate differences in healthcare-seeking behav-
iour of smokers by SEP we will combine the sample used
for the health outcomes described above with a sample
of all other patients indicated as a current smoker after
the 1 September 2006.
Data collection and linkage
We will use linked Hospital Episodes Statistics (HES)
and ONS mortality data to deﬁne frequency of GP and
hospital attendance, frequency of all-cause and cause-
speciﬁc hospitalisation and all-cause and cause-speciﬁc
mortality. We will test these hypotheses using data from
GP practices linked to external data sets only.
These are important hard outcomes for our study. We
have already established that for certain outcomes, such
as cause speciﬁc mortality the linked ONS data are more
accurate.18 While it is possible to investigate these out-
comes using CPRD data from GPs, the data are less
precise and consistently recorded.18 Thus analyses using
linked data are likely to be more precise. Furthermore,
the linked data provide direct evidence about secondary
care attendance of patients via the HES data. Again,
while there are some data about referrals to secondary
care in the main tables of the CPRD, the data are not as
comprehensive as HES data. Our outcomes of interest
occur after September 2006; therefore, we believe that
the linked HES and ONS data will provide sufﬁcient
coverage for these outcomes.
Data analysis
Exposure measures
First time users of the smoking cessation therapies (vare-
nicline or nicotine replacement therapy) will be deﬁned
as people who received at least one prescription of the
product after the 1 September 2006 but with no use of a
related product during the 12 months before the index
date (the ﬁrst date on which a prescription was issued).
Langley et al19 found the smoking cessation prescription
data in the THIN database, which is closely related to
the CPRD, to be highly comparable to national dispens-
ing data. The prescriptions will be deﬁned by the
therapy ﬁle in the CPRD, which contains a list of all pre-
scriptions issued to patients by their GP. Each therapy
record records the date a prescription was issued, the
quantity of drug prescribed and the dose.
The primary analysis will be limited to the ﬁrst treat-
ment episode. This is analogous to an intention-to-treat
analysis in a RCT.20 This ensures that the target param-
eter estimated in the observational study will be compar-
able to the parameter estimated by a RCT. For example,
if patients’ treatment adherence and duration is related
to whether they experience adverse events, then deﬁni-
tions of exposure which are based on treatment adher-
ence may provide unreliable evidence of the causal
effect of the prescription on adverse outcomes. This ana-
lysis framework was described in Hernán et al (2008).
The intuition is that most randomised trials recruit indi-
viduals and then split participants into different treat-
ment arms. This means that comparison groups are
implicitly from ﬁrst treatment. The primary analysis in
an RCT typically reports an intention to treat estimate,
which is the difference in allocation between arms of
the trial based on allocation, rather than the treatment
the participant received. To obtain results that are
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comparable to a randomised trial Hernán argued that
analysts need to construct cohorts that also follow-up
patients from ﬁrst treatment, rather using retrospectively
deﬁned exposures (eg, retrospectively deﬁning exposure
as ever exposed to varenicline).
To mimic an intention-to-treat analysis in an RCT, in
our primary analysis patients who are initially prescribed
nicotine replacement therapy, but later switch to vareni-
cline, will be allocated to nicotine replacement therapy
and vice-versa. We will use an intention-to-treat design
for two reasons. First, while there are theoretical statis-
tical models for estimating the effects of treatment
switching such as marginal structural models, these
methods require the strong assumption that there are
no unmeasured confounders and typically require
detailed data on time-varying confounders, which are
unlikely to be available in the CPRD. Second, to our
knowledge there are no instrumental variable methods
to estimate the effects of switching treatment. However,
we will investigate the number of participants who switch
treatment as a sensitivity analysis.
Outcome measures
Outcome 1: Smoking abstinence
In the CPRD smoking status is indicated by whether the
patient is a current, former or never smoker. As GPs are
paid to record smoking status smoking behaviour is
robustly recorded in the CPRD.21 Marston et al21 found
that 84% of patients had smoking status recorded within
a year of registering at a GP, and that smoking preva-
lence rates by age were similar in CPRD and the Health
Survey of England. Booth et al22 found that the differ-
ence in prevalence of smoking estimate between the
CPRD and the Health Survey for England was less than
1%, and the mean difference was 0.1% (95% CI −1.5%
to 1.7%). Using unpublished data from CPRD sampled
as part of the research reported in Thomas et al13 we
found that 74% of patients prescribed smoking cessation
medication had a subsequent record indicating smoking
status. Of these 66% were indicated as current smokers
and 33% as ex-smokers. We will initially deﬁne a patient
as relapsed if they have any record indicating that the
patient is a current smoker after their ﬁrst prescription
of a smoking cessation therapy. We will not be able to
determine the smoking status of patients who do not
return to the GP. Therefore, we will perform sensitivity
analyses to examine whether the assumptions made
about the smoking status of individuals who are not
observed affect the results. For example, we will conduct
a sensitivity analysis to see if the results are altered by
assuming that patients with missing data have relapsed,
or by assuming that patients with missing outcome data
have achieved abstinence.
Outcome 2: Frequency of GP and hospital attendance
We will deﬁne service use as the number of visits to GP
and hospitals in the 3, 6, 9, 12, 24 and 48 months after
ﬁrst prescription. We will deﬁne GP appointments using
the clinical data ﬁle of the CPRD. This includes all the
diagnoses and symptoms that GPs record about all of
their patients. As with the other outcomes, the vast
majority of diagnoses and symptoms include the date on
which the data were added to the database. We will use
these dates to calculate the number of times each
patient attends primary care. We will deﬁne the hospital
visits outcome using the linked HES data. We will
investigate all-cause hospitalisation and three speciﬁc
causes of hospitalisation: (1) diseases of respiratory
system (ICD-10=J00-J99), (2) cardiovascular disease
(ICD-10=I00-I52) and (3) anxiety and depression
(ICD-10=F31.3, F31.4, F31.5, F32, F40-F48). Causes of
hospitalisation are available for approximately half of
the sample. Again these data contain the date on which
the event occurred, which we will use to deﬁne attend-
ance to secondary care within 3, 6, 9, 12, 24 and
48 months after ﬁrst prescription.
Outcome 3: All-cause and cause-specific mortality
We will deﬁne all-cause and cause-speciﬁc mortality
using the linked ONS mortality data set. These include
the date of death and cause of death using ICD-9 codes.
We will investigate three speciﬁc causes of mortality: (1)
diseases of respiratory system (ICD-10=J00-J99), (2) car-
diovascular disease (ICD-10=I00-I52), and (3) anxiety
and depression (ICD-10=F31.3, F31.4, F31.5, F32,
F40-F48). We will use validated code lists for each
outcome.
Outcome 4: Incident respiratory illness, myocardial
infarction, depression or anxiety
We will deﬁne the adverse event outcomes using the
diagnosis records from the Clinical and Referral ﬁles in
the CPRD. These ﬁles record all the diagnoses that the
GPs input into their computer system. Each record in
the table is given a diagnosis code based on the Read
code categorisation. We will use validated Read code
lists, for the three adverse event outcomes, respiratory ill-
nesses, myocardial infarction or depression and anxiety,
please see the cited papers for Read code lists.23–25 For
eligible patients we will extract all records from the
Clinical and Referral Tables that indicate the patient
either received a speciﬁc diagnosis or were referred for
a speciﬁc diagnosis. As with the therapy records for pre-
scriptions described above, each Clinical and Referral
Record indicates the date the information was inputted
into the system. We will use this date to deﬁne the date
that the diagnosis was performed. We will deﬁne a set of
outcomes within 3, 6, 9, 12, 24 and 48 months after ﬁrst
prescription.
Confounding factors
We will include gender, age in years at time of ﬁrst pre-
scription, previous psychiatric illness/consultation, previ-
ous use of psychotropic medications such as hypnotics,
antipsychotics and antidepressants, previous self-harm,
measures of alcohol consumption where appropriate
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mean/median number of GP visits per year, body mass
index, SEP (deprivation score for area or residence)
and major chronic illness (including: diabetes, cancer,
arthritis) using the Charlson index.26 27 Relevant Read
codes will be identiﬁed either by validated code lists or
by searching for each of these events in the Read code
dictionaries to identify any missing Read codes. Collider
bias is a potential threat to the analysis; this type of bias
occurs when the association between two variables
changes on conditioning of a third variable if the third
variable is affected by the ﬁrst two variables. Collider
bias could occur if we conditioned on events that hap-
pened as a result of the prescription the patient was
issued. To prevent this bias from affecting our results,
we will deﬁne each covariate using data inputted prior
to the ﬁrst prescription.28 If there are missing data in
the covariates we will consider using multiple
imputation.
Follow-up
Follow-up will end with the earliest of either an ‘event’
or censoring due to the end of registration or death.
Statistical analysis
For investigating the effects of varenicline use on each
outcome (long-term smoking cessation, frequency of GP
and hospital attendance, all-cause and cause-speciﬁc
mortality, primary care diagnosis of respiratory illness,
myocardial infarction, depression or anxiety), we will
report a conventional multivariable-adjusted Cox regres-
sion, propensity score regression and instrumental vari-
able analysis.
Analysis 1: Conventional cox regression
In our ﬁrst analysis, a conventional observational ana-
lysis, we will estimate HRs of the outcomes using
Cox-proportional hazards models and the actual pre-
scriptions issued to the patients.29 Each patient’s date of
entry into the cohort will be the date they were ﬁrst pre-
scribed a smoking cessation therapy. The date of exit for
each outcome will be the date on which they ﬁrst have
an event, or are censored due to end of follow-up or
death or leaving the practice. We will report these asso-
ciations adjusted for basic confounders (age and
gender), and results adjusted for all measured covariates
described above.
Analysis 2: Propensity score regression
In our second analysis we will construct a sample of
patients balanced on covariates and risk factors using a
propensity score.30–33 We will construct propensity scores
using a logistic regression of the actual treatment
received on the covariates described above. Therefore,
each participant’s propensity score will be their condi-
tional probability (odds) of receiving varenicline versus
nicotine replacement therapy. We will match each
patient receiving varenicline to another patient receiving
nicotine replacement therapy with the closest propensity
score on a ratio of 1:1 using a nearest neighbour algo-
rithm with no replacement, and matching will be
restricted to the common support region. Patients
outside the common support region are those pre-
scribed varenicline with propensity scores higher than
any patient prescribed nicotine replacement therapy
and vice-versa. We will estimate HRs of the outcomes
using the propensity score matched sample using Cox
regressions using the same entry and exit information as
the conventional Cox regression analysis described
above.
Analysis 3: Instrumental variable analysis
In our third analysis, we will estimate the effects of
smoking cessation therapies on the outcomes using phy-
sicians’ prescribing preferences as instruments for the
prescriptions the GPs issue to their patients. We cannot
directly measure the physicians’ preferences; therefore,
we will use the prescriptions they issued to their previous
patients as a proxy for their preferences. For example, if
the instrument was based on just one previous prescrip-
tion, physicians who previously prescribed varenicline
would be categorised as a varenicline prescriber. As with
our previous studies we will use seven prior prescriptions
to improve the strength of the instruments.13 34 35 Using
multiple prior prescriptions will maximise power. We will
report risk differences in the outcomes using additive
structural mean models estimated via the generalised
method of moments.36–38
We will categorise each of the adverse event outcomes
as occurring within 3, 6, 9, 12, 24 and 48 months of
ﬁrst prescription. We will do this because methods for
conducting survival analysis using instrumental variables
are not well developed. We will use Stata 13.1 SE to
generate all results. The instrumental variable analysis
will be conducted using the ivreg2 command and
psmatch2 will be used to construct the propensity
score.31 39 40 All SEs will be estimated using cluster
robust SEs, which account for clustering of patients
within practices.
Socioeconomic variation in effectiveness of smoking
cessation treatments
This project will use the entire sample of patients indi-
cated as a smoker at any point after 1 September 2006.
We will assign a measure of area level deprivation to
each patient using their home address postcode and to
each GP using the GP postcode. Deprivation levels will
be based on the Indices of Multiple Deprivation (IMD),
which are available from the ONS and are updated
every 2 years. We will use the most recent IMD statistics
preceding the date of entry into the study for each
patient. Although area level deprivation statistics will
only be a proxy for individual level deprivation, these
demonstrate the expected associations with smoking
prevalence.41 We will investigate whether the proportion
of smokers who attend their GP for smoking cessation
treatment differs by IMD, and whether there are any
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differences in prescribing of varenicline versus nicotine
replacement products between areas of high and low
deprivation.
By using individual and GP level IMD codes, we will
investigate whether the effects of smoking cessation ther-
apies differ by IMD at the level of GPs and at the individual
level. We will investigate treatment compliance by report-
ing the total number of prescriptions issued after the
initial prescription. We will estimate the effects of smoking
cessation therapies within subgroups deﬁned by IMD level
at the individual and GP level using the three methods
described above, multivariable-adjusted Cox regression,
propensity score regression and instrumental variable ana-
lysis.29 32 42 The cohort of patients will be deﬁned as
described above. We will report these associations adjusted
for basic confounders (age and gender), and results
adjusted for all measured covariates described above.
Analyses will account for clustering of patients by GPs.
ETHICS APPROVAL, PEER REVIEW, DATA CURATION AND
DISSEMINATION
Access to the CPRD data is governed by its Independent
Scientiﬁc Advisory Committee (ISAC). The empirical
research described in this proposal signiﬁcantly expands
on our existing work. We have received approval for this
project protocol from ISAC (protocol number 15_107).
We will comply with all requirements of ISAC require-
ments for publications based on CPRD data, for
example, including the ISAC study protocol as an appen-
dix to published papers. This protocol has been peer
reviewed separately as part of the NIHR Health
Technology Assessment board’s efﬁcient study designs
call (proposal ID 14/49/94) and the ISAC expert advis-
ory board. The data produced as part of this study will
be made available via a system of managed open access
—interested researchers who obtain necessary approvals
from ISAC will be permitted access to the data generated
during this study.
Key ﬁndings will be collated to form evidence-based
recommendations which will be communicated to the
FDA and the Medicines and Healthcare Products
Regulatory Agency (MHRA), with the aim of improving
the evidence base to inform advice to prescribers and
patients. We will also aim to publish ﬁndings in peer-
reviewed journals and present our work at national and
international conferences.
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